Osteoporosis is a systemic metabolic bone disease characterized by excessive osteoclast formation and increased bone resorption, leading to reduced bone mineral density and heightened fracture risk. Current treatments often focus on inhibiting osteoclast activity, but there remains a need for safe and effective therapeutic agents derived from natural compounds. Hinokitiol, a naturally occurring tropolone derivative isolated from Cupressaceous plants, has shown promising pharmacological properties including anti-inflammatory, antioxidant, and anticancer effects. This study investigates the potential of hinokitiol in suppressing osteoclast differentiation and protecting against estrogen deficiency-induced bone loss. In vitro, hinokitiol significantly inhibited RANKL-induced osteoclast formation in mouse bone marrow macrophages (BMMs), as evidenced by reduced numbers of multinucleated TRAP-positive cells. The compound also suppressed F-actin ring formation, a hallmark of mature osteoclasts, and diminished bone resorption pit formation on bovine cortical bone slices. Mechanistically, hinokitiol attenuated the early activation of MAPK signaling pathways—ERK, p38, and JNK—thereby reducing phosphorylation of downstream transcription factors such as c-Jun, c-Fos, and NFATc1. Notably, hinokitiol did not affect the NF-κB pathway or osteoblast differentiation, suggesting selective inhibition of osteoclastogenesis without impairing bone formation. In vivo, female C57BL/6 mice underwent ovariectomy (OVX) to mimic postmenopausal osteoporosis.ERN1 Antibody medchemexpress Treatment with hinokitiol (10 mg/kg, oral administration every other day for 8 weeks) significantly preserved trabecular bone mass, as confirmed by micro-computed tomography (micro-CT) analysis showing improved BV/TV ratio, increased trabecular number (Tb.VHL Antibody Technical Information N), decreased trabecular separation (Tb.PMID:34618276 Sp), and reduced structure model index (SMI). Histological evaluation revealed fewer TRAP-positive osteoclasts on bone surfaces in hinokitiol-treated mice compared to OVX controls. These findings demonstrate that hinokitiol effectively inhibits RANKL-driven osteoclastogenesis through suppression of MAPK/NFATc1 signaling and protects against OVX-induced bone loss in mice. Thus, hinokitiol emerges as a promising candidate for the development of novel therapeutics targeting osteoclast-mediated bone diseases such as osteoporosis.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
